A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin with Lenalidomide and Dexamethasone (BRd) vs Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Newly Diagnosed Multiple Myeloma Ineligible for Autologous Stem Cell Transplantation (DREAMM-10)